0000000000793559

AUTHOR

Michael Ahdoot

showing 2 related works from this author

Use of multiparametric magnetic resonance imaging and fusion-guided biopsies to properly select and follow African-American men on active surveillance

2019

OBJECTIVES To determine the rate of Gleason Grade Group (GGG) upgrading in African-American (AA) men with a prior diagnosis of low-grade prostate cancer (GGG 1 or GGG 2) on 12-core systematic biopsy (SB) after multiparametric magnetic resonance imaging (mpMRI) and fusion biopsy (FB); and whether AA men who continued active surveillance (AS) after mpMRI and FB fared differently than a predominantly Caucasian (non-AA) population. PATIENTS AND METHODS A database of men who had undergone mpMRI and FB was queried to determine rates of upgrading by FB amongst men deemed to be AS candidates based on SB prior to referral. After FB, Kaplan-Meier curves were generated for AA men and non-AA men who th…

medicine.medical_specialtyeducation.field_of_studybusiness.industryUrologyPopulation030232 urology & nephrologyUrologyGleason grademedicine.disease03 medical and health sciencesProstate cancer0302 clinical medicineInterquartile range030220 oncology & carcinogenesisMedicineAfrican american menbusinesseducationSystematic biopsyFusion BiopsyMultiparametric Magnetic Resonance ImagingBJU International
researchProduct

Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate can…

2021

Abstract Purpose Men with intermediate risk (IR) prostate cancer (CaP) are often excluded from active surveillance (AS) due to higher rates of adverse pathology (AP). We determined our rate of AP in men who underwent multiparametric MRI (MpMRI) with combined biopsy (CB) consisting of targeted biopsy (TB) and systematic biopsy (SB) prior to radical prostatectomy (RP). Methods A retrospective review was conducted of men with Gleason Grade Group (GG) 2 disease who underwent RP after SB alone or after preoperative MRI with CB. AP was defined as either pathologic stage T3a (AP ≥ T3a) or pathologic stage T3b (AP ≥ T3b) and/or GG upgrading. Rates of AP were determined for both groups and those who…

Image-Guided BiopsyMalePathologymedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyDiseaseGleason gradeLogistic regression03 medical and health sciencesProstate cancer0302 clinical medicineBiopsymedicineHumansRetrospective StudiesProstatectomymedicine.diagnostic_testbusiness.industryProstatectomyProstateProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseMagnetic Resonance ImagingOncology030220 oncology & carcinogenesisbusinessIntermediate riskUrologic Oncology: Seminars and Original Investigations
researchProduct